NV 52

Drug Profile

NV 52

Alternative Names: NV-07β

Latest Information Update: 23 Dec 2010

Price : $50

At a glance

  • Originator Novogen
  • Class Anti-inflammatories; Isoflavones
  • Mechanism of Action Arachidonic acid inhibitors; Nitric oxide inhibitors; Superoxide dismutase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 23 Dec 2010 NV 52 is still in phase I development for Inflammatory bowel disorders in Australia
  • 10 Aug 2006 Novogen has initiated enrolment in a phase I trial for Inflammatory bowel disease in Australia
  • 27 Mar 2006 Novogen has completed a phase I trial in Inflammatory bowel disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top